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Abstract
A42yearoldwomanwasadmittedtoourhospitalforinvestigationofeosinophilia.Therewerenofindings
from the physical examination of the lungs and heart. The echocardiography showed a segmental
hypokinesia of the interventricular septum and the apex causing left ventricular dysfunction with an
ejection fraction 45% and mild pericardial effusion. Cardiac magnetic resonance was performed, for
detectionoflesionsassociatedwiththeunderlinedisease,usingelectrocardiogram-triggeredT2-weighted
and T1-weighted multislice spin-echo images (before and after an intravenous bolus of gadolinium).
The analysis of T2-weighted images revealed increased signal on the mid part of interventricular
septum, suggesting myocardial oedema. In the delayed-enhanced images, areas of late phase
gadolinium enhancement (indicative of fibrosis) were identified in the mid part of interventricular
septum. Methylprednisolone therapy was started. The patient had follow-up echocardiographic
examination every month and on sixth month improvement of left ventricular dysfunction was shown
with an ejection fraction 55%.
In conclusion our case is a typical Churg Strauss Syndrome with characteristic myocardial involvement
whichimprovedaftercorticosteroidtreatment.Thecardiacmagneticresonancehassignificantrolefor
early and accurate detection and differentiation of myocardial damage even in preserved cardiac wall
motion and cavity size.
Introduction
ChurgStrauss syndrome(CSS) isa rarenecrotizing systemic
vasculitis [1]. Inthe initial phase asthma and rhinitisare the
most common manifestations of the syndrome. The next
phaseofthediseaseistheperipheralandtissueeosinophilia
and finally comes the vasculitis of different organs with life
threatening results [2,3]. Cardiac involvement is frequent in
patients with CSS and predicts the final prognosis [4,5].
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A 42 year old Greek woman was admitted to our hospital
for investigation of eosinophilia. On admission, the white
blood cells were 24, 2 K/μl with 62.8% the eosinophils.
She had suffered from bronchial asthma and recurrent
sinusitis for the last 4 and 6 years respectively. There were
no findings from the physical examination of the lungs
and heart. The blood pressure was 110/70 mm/Hg
whereas the electrocardiogram and chest x-ray were
normal. The echocardiography showed a segmental
hypokinesia of the interventricular septum and the apex
causing left ventricular dysfunction with an ejection
fraction (EF) 45% and mild pericardial effusion. Valvular
disease or thrombus formations were excluded. Cardiac
enzymes as serum creatine kinase-MB and troponin T were
in normal levels. Cardiac magnetic resonance (CMR) was
performed, for detection of lesions associated with the
underline disease, using electrocardiogram-triggered T2-
weighted and T1-weighted multislice spin-echo images
(before and after an intravenous bolus of 0.1 mmol/kg
gadolinium). The analysis of T2-weighted images revealed
i n c r e a s e ds i g n a lo nt h em i dp a r to fi n t e r v e n t r i c u l a r
septum, suggesting myocardial oedema. In the delayed-
enhanced images, areas of late phase gadolinium enhance-
ment (indicative of fibrosis) were identified in the mid
part of interventricular septum. The EF of the left ventricle
(LV) was 50% whereas a mild pericardial effusion was
also noted (Figure 1 and Figure 2). Other causes of
eosinophilia were excluded by bone marrow biopsy.
Therapy was started with methylprednisolone 32 mg per
day. The patient had follow-up echocardiographic exam-
ination every month and on sixth month improvement of
left ventricular dysfunction was shown with an EF 55%.
Discussion
CSS is a rare necrotizing vasculitis of small blood vessels
(arteries and veins), with eosinophilic infiltration of them
[6]. An estimation about the frequency of this particular
vasculitis in the population is 2.4 - 6.8 cases in 1.000.000
patient per year [7]. Late onset of asthma, nasal polypus
and sinusitis are the first manifestations of the syndrome
in the early phase [2,7,8]. The second clinical phase is
tissue eosinophilia and pulmonary infiltrations, while the
last phase of the syndrome is vasculitis of many organs
such as skin, gastrointestinal, lung, heart and peripheral
nervous system [3]. This particular phase is life threaten-
ing, especially when there is heart and gastrointestinal
involvement [3,7]. The syndrome affects both males and
females and the mean age of presentation is usually
40 years old [9]. The asthma and its corticosteroid therapy,
sometimes cover, for a period of time, the manifestations
of vasculitis [7,9]. The onset of the vasculitic phase usually
reduce the severity of the asthma, but its presence is
longstanding in approximately 80% of the patients [7,10].
The American College of Rheumatology developed in
1990 the diagnostic criteria for CSS. Four of the 6 criteria
make the diagnosis almost accurate. The criteria include
asthma, eosinophilia (more than 10% of the white blood
cell count), pulmonary infiltrates, mononeuropathy or
polyneuropathy, paranasal sinus abnormality and final
extravascular eosinophil infiltration on biopsy [1,6,10].
Usually the asthma is followed by peripheral and tissue
eosinophilia with final result the transient pulmonary
infiltrations. The patients have findings in their chest x-ray
ranging from 62-77% [9]. The combination of asthma and
eosinophilia helps to distinguish this particular syndrome
from other vasculitis like Wegener and microscopic
Figure 1. Short axis delayed-enhanced image of left ventricle
after injection of gadolinium, indicative of inflammation in
the interventricular septum.
Figure 2. Four chamber delayed-enhanced image of left
ventricle after injection of gadolinium, indicative of
inflammation in the interventricular septum.
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leukemias andhypereosinophilic syndromeinwhichthere
is absence of asthma [3,7]. The final stage is the vasculitis
and it involves many organs like skin, lungs, nervous
system, gastrointestinal tract, kidneys and heart. Common
manifestations are purpura, peripheral neuropathy, seg-
mental necrotising glomerulonephritis, pleural effusion,
gastrointestinal perforation and haemorrhage. The last
usually predicts poor prognosis [6,7,9]. It should be noted
also that CSS is ANCA (antineutrophil cytoplasmic
antibodies) associated vasculitis. Approximately 70-80%
of the patients with CSS are ANCA positive (especially
with the perinuclear type) [6,10]. The presence of ANCA
correlates with renal involvement, while the absence
correlates with cardiac manifestations [6].
Cardiac involvement is common in CSS and it has
important prognostic role. It occurs in 40-47% of the
cases [4,5]. More often causes epicardial coronary vascu-
litis, valvular disease, congestive heart failure due to
eosinophilic myocarditis, pericarditis and pericardial
effusion [2,6,10,11]. Myocardial infraction is the result
of the epicardial coronary vasculitis [2], while the
pericardial effusion might cause congestive symptoms
and rarely cardiac tamponade [6,9]. The fluid is exudate
with marked eosinophilia and low levels of glucose. It has
also been reported the case of atraumatic intra- pericardial
thrombosis [5]. The early diagnosis of the cardiac
involvement has major importance because the develop-
ment of heart failure makes the prognosis poor [12]. The
diagnostic tools are echocardiography and cardiac mag-
netic resonance (CMR). The last has important role
because findings like myocardial fibrosis with subendo-
cardial location, oedema and hyperemia have early
appearance and echocardiography cannot detect them [4].
Corticosteroids are the first line therapy of CSS causing
remission and survival improvement. Prednisone 1mg/kg
day is the recommended dose for 1 month with gradual
taper up to 1 year [7,9]. When the recurrences are frequent,
or there is a serious form of necrotizing vasculitis in an
organ like the gastrointestinal tract or the heart, then the
usage of cyclophosphamide is recommended. The combi-
nation therapy controls the relapses of disease but has no
advantage in survival. In addition this particular therapy
has serious side effects with most important the risk of
urological malignancies. This results from the accumula-
tion of the metabolite acrolein in the bladder [7].
In conclusion our case is a typical CSS syndrome with
characteristic myocardial involvement which improved
after corticosteroid treatment. Since cardiac involvement is
a leading cause of mortality it is crucial to detect cardiac
involvement as early as possible [12]. The CMR has
significant role for early and accurate detection and
differentiation of myocardial damage even in preserved
cardiac wall motion and cavity size.
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